favezelimab,pembrolizumab
merck
['hodgkin', 'favezelimab', 'nhl', 'pembro', 'lymsm', 'imab ']
ckpi refractory hodgkin is unmet need. favezelimab (lag-3i) + pembro has actively in about third of patients #ash22 #lymsm 
BMT & Cellular Therapy | #Lymphoma | Co-Chair @ASTCT CoPG | #bmtsm #CARTcell #lymsm | Personal views | Physician ? Provider | ???? ?? ???? ??